Processa Pharmaceuticals (PCSA) Non-Current Deferred Tax Liability (2012 - 2021)
Processa Pharmaceuticals' (PCSA) quarterly Non-Current Deferred Tax Liability came in at $181752.0 in Q3 2021, down 85.4% YoY from $1.2 million in Q3 2020, and down 40.25% on a QoQ basis from $304194.0 in Q2 2021.
Processa Pharmaceuticals (PCSA) Non-Current Deferred Tax Liability (2012 - 2021) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $181752.0 in Q3 2021.
- Quarterly Non-Current Deferred Tax Liability fell 85.4% year-over-year to $181752.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $181752.0 (down 85.4% YoY) and the FY2020 annual result came in at $530611.0, down 65.36% from the prior year.
- Non-Current Deferred Tax Liability declined to $181752.0 in Q3 2021, from $304194.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.5 million in Q2 2018 to a low of $1782.0 in Q3 2018.
- A 4-year average of $969678.2 and a median of $887910.0 in 2020 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2019 — Non-Current Deferred Tax Liability tumbled 99.93% — and 2020, when it surged 73730.86%.
- Tracing PCSA's Non-Current Deferred Tax Liability over 4 years: stood at $2.1 million in 2018, then fell by 28.24% to $1.5 million in 2019, then plunged by 65.36% to $530611.0 in 2020, then slumped by 65.75% to $181752.0 in 2021.
- The last three Non-Current Deferred Tax Liability figures came in at $181752.0 (Q3 2021), $304194.0 (Q2 2021), and $441363.0 (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 181,752.00 |
| Sep 30, 2021 | 181,752.00 |
| Jun 30, 2021 | 304,194.00 |
| Jun 30, 2021 | 304,194.00 |
| Mar 31, 2021 | 441,363.00 |
| Mar 31, 2021 | 441,363.00 |
| Dec 31, 2020 | 530,611.00 |
| Dec 31, 2020 | 530,611.00 |
| Sep 30, 2020 | 1.25 Mn |
| Sep 30, 2020 | 1.25 Mn |
| Jun 30, 2020 | 1.32 Mn |
| Jun 30, 2020 | 1.32 Mn |
| Mar 31, 2020 | 1.40 Mn |
| Mar 31, 2020 | 1.40 Mn |
| Dec 31, 2019 | 1.53 Mn |
| Dec 31, 2019 | 1.53 Mn |
| Sep 30, 2019 | 1,782.00 |
| Sep 30, 2019 | 1,782.00 |
| Jun 30, 2019 | 1,782.00 |
| Jun 30, 2019 | 1,782.00 |